5-(6-(1,4-diazepan-1-yl)pyrazin-2-yl)-1H-3-methylindazole | 1601619-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-(6-(1,4-diazepan-1-yl)pyrazin-2-yl)-1H-3-methylindazole
• 英文别名: 5-[6-(1,4-diazepan-1-yl)pyrazin-2-yl]-3-methyl-2H-indazole
• CAS: 1601619-63-9
• 化学式: C₁₇H₂₀N₆
• 分子量: 308.386
• InChiKey: FWLLRTWYRORQAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  69.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(6-(1,4-diazepan-1-yl)pyrazin-2-yl)-1H-3-methylindazole 在 盐酸 作用下， 以 乙醚 为溶剂， 以99%的产率得到5-(6-(1,4-diazepan-1-yl)pyrazin-2-yl)-1H-3-methylindazole hydrochloride
  参考文献：
  名称：

  In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma

  摘要：

  A series of 2,3,6-pyrazine Rho Kinase inhibitors were optimized for in vivo activity for topical ocular dosing. Modifications of the 2-(piperazin-1-yl) pyrazine derivatives produced compounds with improved solubility and physicochemical properties. Modifications of the 6-pyrazine substituent led to improvements in in vitro potency. Compound 9 had the best in vitro and in vivo potency of EC50 = 260 nM with a 30% reduction of IOP in a non-human primate model at a dose of 0.33%. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.017
• 作为产物：
  描述：

  1,4-二氮杂环庚烷-1-甲酸叔丁酯 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二甲基亚砜 为溶剂， 反应 12.0h， 生成 5-(6-(1,4-diazepan-1-yl)pyrazin-2-yl)-1H-3-methylindazole
  参考文献：
  名称：

  In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma

  摘要：

  A series of 2,3,6-pyrazine Rho Kinase inhibitors were optimized for in vivo activity for topical ocular dosing. Modifications of the 2-(piperazin-1-yl) pyrazine derivatives produced compounds with improved solubility and physicochemical properties. Modifications of the 6-pyrazine substituent led to improvements in in vitro potency. Compound 9 had the best in vitro and in vivo potency of EC50 = 260 nM with a 30% reduction of IOP in a non-human primate model at a dose of 0.33%. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.017

文献信息

• In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma
  作者：Hwang-Hsing Chen、Abdelmoulah Namil、Bryon Severns、Jennifer Ward、Curtis Kelly、Colene Drace、Marsha A. McLaughlin、Shenouda Yacoub、Byron Li、Raj Patil、Naj Sharif、Mark R. Hellberg、Andrew Rusinko、Iok-Hou Pang、Keith D. Combrink

  DOI：10.1016/j.bmcl.2014.03.017

  日期：2014.4

  A series of 2,3,6-pyrazine Rho Kinase inhibitors were optimized for in vivo activity for topical ocular dosing. Modifications of the 2-(piperazin-1-yl) pyrazine derivatives produced compounds with improved solubility and physicochemical properties. Modifications of the 6-pyrazine substituent led to improvements in in vitro potency. Compound 9 had the best in vitro and in vivo potency of EC50 = 260 nM with a 30% reduction of IOP in a non-human primate model at a dose of 0.33%. (C) 2014 Elsevier Ltd. All rights reserved.